Response to Comments: MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers

This document is a response-to-comments notice for the MolDX Local Coverage Determination DL39648 concerning gene expression profile tests for decision-making in castration-resistant and metastatic prostate cancer. It provides administrative timeline information (comment period 10/12/2023–11/25/2023; notice begins 08/08/2024; effective 09/22/2024) but does not include any clinical coverage criteria, limitations, documentation requirements, or frequency limits in the provided text.